Ultragenyx Pharmaceutical Inc
(FRA:UP0)
€
46.2
-0.4 (-0.86%)
Market Cap: 4.31 Bil
Enterprise Value: 3.76 Bil
PE Ratio: 0
PB Ratio: 13.42
GF Score: 81/100 Ultragenyx Pharmaceutical Inc at Cowen Healthcare Conference (Virtual) Transcript
Mar 01, 2021 / 07:00PM GMT
Release Date Price:
€117
(+5.41%)
Yaron Benjamin Werber
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst
Okay. Good afternoon, everybody, and thank you once again for joining us for the 41st Annual Cowen Healthcare Conference. I'm Yaron Werber, biotech analyst here at Cowen, with my colleague, Brendan Smith, and my team. And it's a great pleasure for both of us to moderate the next session with Emil Kakkis, CEO and President of Ultragenyx.
If you have any questions, by all means, you can either throw them into the Wall Street Webcast, and I have it open here, and we'll read them anonymously on your behalf. Or send them either to Brendan or myself, and we'll be happy to take them as they come in.
Emil, great to see you. Thanks for joining us.
Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - President, CEO & Director
Thanks for having me, Yaron. Happy to be here.
Questions & Answers
Yaron Benjamin Werber
Cowen and Company, LLC, Research Division - MD & Senior Biotechnology Analyst
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot